CN Patent

CN112204011A — 一种甲磺酸乐伐替尼新晶型及其制备方法

Assigned to Chengdu Easton Biopharmaceuticals Co Ltd · Expires 2021-01-08 · 5y expired

What this patent protects

一种甲磺酸乐伐替尼的新晶型、其制备方法及制备治疗癌症的药物中的用途。

USPTO Abstract

一种甲磺酸乐伐替尼的新晶型、其制备方法及制备治疗癌症的药物中的用途。

Drugs covered by this patent

lenvatinib-mesylate (LENVATINIB MESYLATE)

Patent Metadata

Patent number: CN112204011A
Jurisdiction: CN
Classification: —
Expires: 2021-01-08
Drug substance claim: No
Drug product claim: No
Assignee: Chengdu Easton Biopharmaceuticals Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.